register

News & Trends - MedTech & Diagnostics

Two medtechs sign commercial agreement to expand access to precision oncology therapy

Health Industry Hub | April 13, 2022 |

MedTech News: Hospitals increasingly seek flexible and interoperable simulation and guidance technology to meet the major need for radiotherapy solutions across both developed and developing markets.

Two medtech companies, GE Healthcare and Elekta, have signed a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy.

As many as 50–60% of all cancer patients require radiation therapy which requires high quality imaging and sophisticated delivery equipment and software to precisely target tumours while sparing healthy tissue. Precision imaging is fundamental to determining the size, shape and characteristics of tumours and differentiating between healthy tissues. Delivering the most appropriate dose requires advanced patient positioning, motion management technologies and state-of-the-art techniques.

Combining GE Healthcare’s imaging solutions with Elekta’s radiation therapy solutions will result in an even more compelling offering for hospitals, and ultimately their patients.

You may also like: GenesisCare spin-off to form biggest cardiology care business

“Access to radiation therapy is a significant challenge in several parts of the globe. We are pleased that this collaboration is a step in the right direction to make more comprehensive precision health solutions more readily available,” said Jan Makela, President & CEO Imaging, GE Healthcare. “Cancer care can only be improved if those in the field work together and this is one of several partnerships that we are pursuing, for the benefit of caregivers and patients, as we build out our Oncology offerings to help enable more precise care.”

Elekta CEO, Gustaf Salford, said “We are driven by our hospitals and cancer centres’ preferences and their need for comprehensive solutions in effective, efficient and safe cancer care. Therefore, we’re excited about this collaboration with GE Healthcare. We have many mutual health care providers who see clear synergies and advantages with our respective, strong product portfolios. This will allow us to jointly promote solutions for each cancer centre’s needs. Elekta strives to assure that hospitals and cancer centres can create seamless ecosystems that facilitate efficient end-to-end cancer care.”

GE Healthcare and Elekta will continue to offer their own solutions using standard interoperability and facilitate interfaces with any vendor’s systems.

The agreement is non-exclusive, meaning each party can continue to cooperate with other partners. Separately, both companies are eager to improve interoperability and streamline workflows in radiation oncology.

The Health Industry Hub news and professional development content are copyright protected and access is provided under individual user licenses.

Visit https://www.healthindustryhub.com.au/membership/ and T&Cs for more information.


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.